12 Best Multibagger Stocks to Buy Heading into 2026

Page 10 of 11

2. Gossamer Bio, Inc. (NASDAQ:GOSS)

Market Cap: $823.98 Million

Price Return over 1-Year: 309.17%

Upside Potential: 152.10%

Number of Hedge Fund Holders: 36

With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

Amid the company’s continued efforts to advance seralutinib across two late-stage pulmonary hypertension programs, analyst confidence in Gossamer Bio, Inc. (NASDAQ:GOSS) remains high.

By the end of Q3 2025, Gossamer Bio, Inc. (NASDAQ:GOSS) confirmed completion of enrollment in its global Phase 3 PROSERA study for pulmonary arterial hypertension, with 390 patients enrolled. Management reported the double-blind, placebo-controlled trial evaluating seralutinib on top of background therapy, with a primary endpoint focused on six-minute walk distance at 24 weeks.

Meanwhile, Gossamer Bio, Inc. (NASDAQ:GOSS) expects topline data from PROSERA to come out in February 2026. At the same time, the company reported activation of the first clinical site for its registrational Phase 3 SERANATA study in pulmonary hypertension associated with interstitial lung disease. With this, the company sees seralutinib’s clinical scope broadening into a second indication.

Amid this clinical progress, Gossamer Bio, Inc. (NASDAQ:GOSS) has received positive analyst sentiment. Piper Sandler analyst Yasmeen Rahimi reiterated a “Buy” rating on December 9, 2025, while setting a $15.00 price target. Earlier, on November 19, 2025, the company received a “Buy” rating and a $10.00 price target from H.C. Wainwright analyst Patrick Trucchio. Trucchio cited the steady advancement of both PROSERA and SERANATA, viewing the upcoming PAH readout and expansion into PH-ILD as key milestones reflecting confidence in seralutinib’s long-term potential.

Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage biopharmaceutical company, develops seralutinib to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Page 10 of 11